Seer, Inc. (NASDAQ:SEER) CEO Sells $18,072.32 in Stock

Seer, Inc. (NASDAQ:SEER) CEO Omid Farokhzad sold 8,068 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.24, for a total value of $18,072.32. Following the completion of the sale, the chief executive officer now directly owns 1,428,217 shares of the company’s stock, valued at approximately $3,199,206.08. This represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Seer Stock Performance

Shares of NASDAQ SEER opened at $2.28 on Thursday. The business has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.07. Seer, Inc. has a twelve month low of $1.51 and a twelve month high of $2.63.

Institutional Trading of Seer

Institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in shares of Seer in the 2nd quarter valued at about $30,000. Y Intercept Hong Kong Ltd acquired a new position in Seer in the fourth quarter valued at approximately $36,000. Quadrature Capital Ltd boosted its stake in Seer by 301.7% in the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock valued at $112,000 after acquiring an additional 42,875 shares during the period. XTX Topco Ltd bought a new position in shares of Seer during the third quarter valued at approximately $123,000. Finally, Barclays PLC raised its position in shares of Seer by 34.1% during the 3rd quarter. Barclays PLC now owns 64,426 shares of the company’s stock worth $127,000 after purchasing an additional 16,382 shares during the period. 75.20% of the stock is owned by institutional investors and hedge funds.

Seer Company Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.